Ovagen Prices

Prices refresh daily · 4 a.m. ET

9 vendors with a listing · 1 with an issuer-verified COA · lowest 10mg from $39.57 · checked

Where to buy Ovagen: 9 vendors compared

1 vendor match the selected filters
Prices for Ovagen by vendor
VendorPriceActions
3-test panel COA verified Freedom DiagnosticsPurity, Identity, ContentView COA$55.00 20mg package Checked Buy Ovagen from True Lab Peptides

Ovagen listing prices

The blue line is the lowest in-stock package total each collected day; the band is the next four cheapest.

Method

Package totals before coupons and shipping. Strengths can differ between vendors and dates, so this is not a per-mg index. A day without a collection stays a gap.

31 collected days –

Lowest package price, with the next four cheapest as a bandLowest in-stock package total: 31 collected days, Oct 22, 2026 – Nov 21, 2026. The blue line is the lowest in-stock package total each collected day; the band is the next four cheapest.$0$50$100$150Oct 22, 2026: $49.99 lowest, $79.97 at the top of the fiveOct 23, 2026: $49.99 lowest, $99.99 at the top of the fiveOct 24, 2026: $49.99 lowest, $99.99 at the top of the fiveOct 25, 2026: $49.99 lowest, $99.99 at the top of the fiveOct 26, 2026: $49.99 lowest, $99.99 at the top of the fiveOct 27, 2026: $79.97 lowest, $99.99 at the top of the fiveOct 28, 2026: $79.97 lowest, $99.99 at the top of the fiveOct 29, 2026: $49.99 lowest, $79.99 at the top of the fiveOct 30, 2026: $49.99 lowest, $79.99 at the top of the fiveOct 31, 2026: $79.97 lowest, $79.99 at the top of the fiveNov 1, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 2, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 3, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 4, 2026: $79.97 lowest, $79.99 at the top of the fiveNov 5, 2026: $65.00 lowest, $79.99 at the top of the fiveNov 6, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 7, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 8, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 9, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 10, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 11, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 12, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 13, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 14, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 15, 2026: $65.00 lowest, $79.99 at the top of the fiveNov 16, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 17, 2026: $65.00 lowest, $79.99 at the top of the fiveNov 18, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 19, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 20, 2026: $49.99 lowest, $79.99 at the top of the fiveNov 21, 2026: $43.97 lowest, $79.99 at the top of the five$43.97$79.99Oct 22, 2026Nov 1, 2026Nov 11, 2026Nov 21, 2026
Latest $43.97$49.99$65.00$79.99—

Before coupons (table prices apply them), the lowest Ovagen package price moved from $49.99 on Oct 22, 2026 to $43.97 on Nov 21, 2026; 6 vendors reached the cheapest five.

Vendors in the cheapest five

6
Vendors that appeared in the five cheapest listings, with collected days and the last top-five package price.
VendorDays in fiveLast top-five package
BioLongevity Labs 31$43.97 -45.0%
Cenexa Labs 28$79.99
Eppix Labs 24$49.99
PX1 Research 17$65.00
Pinnacle Performance 6$99.99
NextSelf Labs 5$64.99

Current market data

Ovagen Price Report

How this report is calculated

The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded. COA coverage counts vendors with an exact compound-and-strength match in the listing-evidence projection; report dates and lot identifiers remain specific to each certificate.

Compare current Ovagen prices and matching laboratory evidence.

Checked through

The lowest current 10mg cost for Ovagen is $39.57 from BioLongevity Labs. The median across vendors is $55.25.

Lowest 10mg cost
$39.57BioLongevity Labs
Median 10mg cost
$55.25One normalized offer per vendor
Lowest package total
$39.57BioLongevity Labs · package size may differ
Vendors with matching verified COAs
1of 9 vendors · Ovagen

What the market shows

PeptidePrices found 9 in-stock listings from 9 vendors, checked through Nov 21, 2026. The lowest 10mg cost is 28% below the vendor median of $55.25; 4 vendors (44%) fall below that median. 1 of 9 vendors (11%) have an exact issuer-verified COA for at least one listed Ovagen strength.


Research and literature

Ovagen: The Kidney Tripeptide Studied for Tissue Protection and Aging

Ovagen is a tripeptide, a three-amino-acid chain also called T-35, studied as a kidney bioregulator [8][1]. A bioregulator here is a short peptide proposed to switch tissue-specific gene programs on or off. The sources name no parent protein; the closest natural material is a polypeptide complex isolated from calf kidney, tested alongside the tripeptide [1]. A 2021 systematic review lists the peptide as Ovagen [8].

A 2014 paper by Vladimir Khavinson and colleagues at the I. P. Pavlov Institute of Physiology in St. Petersburg reported that Ovagen regulated signaling molecules in aging kidney cell cultures [1]. A separate 2014 study found that the kidney tripeptides T-31 and T-35, with the pineal tetrapeptide epitalon, limited tubular injury, oxidative stress and energy failure in experimental rhabdomyolysis [3]. Khavinson's laboratory framed these short peptides as organ-specific regulators that act on gene expression [5][8].

The research potential is concentrated in kidney protection: acute injury from gentamicin, cisplatin and ischemia-reperfusion, plus aging-related decline [4][6][7]. As of October 2026, Ovagen has no approved human drug product and no registered clinical trial; the evidence is preclinical, and the sources contain no human safety or pharmacokinetic data. WADA's 2026 list does not name Ovagen; its S0 class covers substances with no current government approval for human therapeutic use that no later section addresses [11]. The NCAA banned list does not name it either, and its peptide-hormone class carries a catch-all for related substances [12]. For a short peptide, identity and purity are practical questions; the guide to reading a COA explains the tests tracked in the COA library.

Key takeaways

  • Ovagen is a three-amino-acid peptide, also called T-35 [1], studied as a kidney bioregulator; a 2021 review also lists it for liver protection [8].
  • In rat models, Ovagen improved urine output, creatinine handling and sodium balance after cisplatin, gentamicin and ischemia-reperfusion injury, and in old rats [4][6][7].
  • No human trial of Ovagen appears in the sources reviewed or on ClinicalTrials.gov, and Ovagen has no approved human drug product; WADA's S0 class covers unapproved substances and the NCAA peptide-hormone class covers related ones [11][12].

How it works

Gene regulation through direct DNA binding

Ovagen may work by binding DNA and changing which genes a kidney cell reads. DNA is the cell's instruction molecule, and transcription is the step that copies a gene into RNA, the working copy used to build a protein. The minor groove is the smaller of the two spiral grooves that run along the DNA double helix, and docking is a computer method that fits a molecule into a three-dimensional structure to estimate how well it binds.

The 2016 docking study built models for 19 short peptides and placed Ovagen at ctcc DNA sites [5]. The same paper placed Bronchogen, a four-amino-acid peptide studied for lung cells, at the same ctcc site [5][8]. The result suggests that short peptides can share a DNA site even when their tissue effects differ, though the paper does not test that idea in cells [5][8].

The 2014 renal culture study reached a different modeling result: Ovagen and Cartalax formed their most favorable complexes with a repeating AT sequence in the minor groove [2]. Both results are models, not measured structures. The 2021 review calls Ovagen a DNA binder, and the two papers agree on the general idea of direct DNA contact while disagreeing on the preferred site [2][5][8].

Cell renewal and the aging kidney

Ovagen may slow some features of kidney cell aging by shifting the balance toward division and away from growth arrest. Cell senescence is a state in which a cell stops dividing and releases inflammatory signals, and it accumulates in the kidney with age. p16, p21 and p53 are proteins that brake the cell cycle, and SIRT-6 is a sirtuin, an enzyme linked to DNA repair and longevity.

In primary kidney cell cultures, Ovagen (T-35) changed the expression of MMP-14, a gelatinase that breaks down and remodels the matrix between cells [1]. The study measured Ki-67 and p53 as cell-renewal markers and reported that the calf kidney polypeptide complex and T-31 activated renewal, while Ovagen's main signal was MMP-14 [1]. IL-8, an inflammatory chemokine, was also measured as an immune-response marker.

In aging renal cell cultures, Cartalax and Ovagen increased proliferation and lowered p16, p21 and p53, while raising SIRT-6 in both young and aged cultures [2]. The effect appeared in cells, not in intact kidney, and the abstract does not report a dose or a percent change.

Transport into kidney cells

Ovagen may reach its target through nutrient transporters on the cell surface. LAT1 and LAT2 are amino acid transporters, proteins that carry neutral amino acids across the cell membrane. PEPT1 is a di- and tripeptide transporter, a protein that carries two- and three-amino-acid peptides into the cell. A transporter is a gate, and a peptide that fits the gate can enter without a dedicated receptor.

The 2023 docking study modeled 26 biologically active ultrashort peptides against LAT1, LAT2, PEPT1 and PEPT2, with 8,400 di- and tripeptides as comparators [10]. Ovagen ranked fourth of 26 at LAT1 and tenth at PEPT1. It ranked 24th at LAT2 and 25th at PEPT2, so the strongest predicted routes were LAT1 and PEPT1.

A 2022 review of POT and LAT carriers proposes that transporter expression helps explain why short peptides act on some tissues and not others [9]. The review covers Ovagen among the peptides, but the transport evidence for it is computational. No experiment in the sources measured how much of the tripeptide enters kidney cells or how quickly it leaves.

Nephroprotection after acute injury

Ovagen may protect kidney tubules during acute kidney injury, a sudden loss of filtering function that can follow infection, drugs or reduced blood flow. The tubules are the long channels that reabsorb water, sodium and glucose after the glomerulus filters blood. Oliguria is low urine output, azotemia is the buildup of urea and creatinine, and proteinuria is protein leaking into urine.

In experimental rhabdomyolysis, muscle breakdown releases myoglobin, a heme protein that injures tubules; the kidney tripeptides T-31 and T-35, with epitalon, limited tubular injury, oxidative stress and energy failure [3]. In cisplatin-induced acute renal failure, Ovagen normalized diuresis, urine creatinine concentration and excretion, glomerular filtration rate and absolute sodium reabsorption, and it reduced urine protein [4].

In gentamicin and ischemia-reperfusion models, Ovagen prevented oliguria and azotemia, lowered proteinuria and sodium excretion, prevented the fall in antioxidant enzyme activity, suppressed lipid peroxidation and normalized energy supply [6]. Lipid peroxidation is oxidative damage to membrane fats, and antioxidant enzymes are the cell's defense against it.

In old rats, the kidney polypeptide complex and the tripeptides Cartalax and Ovagen raised diuresis 1.2 to 1.4 times, and Ovagen raised sodium excretion 1.6 times, with no morphological or antioxidant evidence of nephrotoxicity [7].

What has been studied in humans

As of October 2026, no human study of the Ovagen tripeptide has been published, and a ClinicalTrials.gov search on October 23, 2026 returned no registered trial. The record in the sources reviewed is entirely preclinical: primary kidney cell cultures and rats [1][6].

No human pharmacokinetic study shows how much of the tripeptide reaches kidney tissue, and no human safety study reports adverse events. Most of the animal work uses acute injury models, and the abstracts do not report long-term follow-up, so the studies cannot show whether benefit lasts or whether repeated exposure is safe [3][7].

None of the cited studies used human participants. The cell work uses primary kidney cultures, and the abstracts do not always state the species [1][2]. A first-in-human study would need a characterized drug substance, a measured exposure profile and a toxicology package; the sources reviewed contain none of that for Ovagen.

Lab and animal studies

Preclinical means work in cells, tissue or animals before a treatment reaches human testing. The Ovagen literature is small and almost entirely renal. The 2021 and 2022 reviews list hepatoprotection, but none of the primary papers tested liver injury [8][9].

In primary kidney cell cultures, Ovagen (T-35) changed MMP-14, a gelatinase that remodels the matrix between cells, while the polypeptide complex and T-31 activated cell renewal [1]. In aging cultures, Ovagen raised proliferation and lowered p16, p21 and p53, three brakes on the cell cycle, while raising SIRT-6, a sirtuin linked to DNA repair and longevity [2]. The same paper built models of Ovagen in the DNA minor groove at a repeating AT sequence, a proposed route to gene regulation rather than a measured one [2].

Most of the animal work tests acute kidney injury. In rhabdomyolysis, the kidney tripeptides T-31 and T-35, with epitalon, limited tubular injury, oxidative stress and energy failure [3]. In cisplatin nephropathy, Ovagen normalized diuresis, creatinine excretion, glomerular filtration and sodium reabsorption [4]. In gentamicin and ischemia-reperfusion injury, Ovagen prevented oliguria, azotemia and proteinuria and preserved antioxidant enzymes [6].

In old rats, the kidney polypeptide complex and the tripeptides Cartalax and Ovagen increased urine output 1.2 to 1.4 times, and Ovagen increased sodium excretion 1.6 times, without morphological or antioxidant evidence of nephrotoxicity [7]. Doses are not in the abstracts, the models are mostly acute, and the studies come from a small group of laboratories. No primate or human tissue study appears in the sources reviewed.

Research in detail

Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging

Primary kidney cell culture study during in vitro aging with peptide treatment · Primary kidney cell cultures during in vitro aging

The calf kidney polypeptide complex and T-31 activated cell renewal, while Ovagen (T-35) targeted MMP-14; Ki-67, p53 and IL-8 were also measured.

Evidence scope: Abstract reviewed; full text not read. The abstract does not give peptide concentrations, culture species, group sizes or statistics, and it lists a single institute affiliation.

Tripeptides slow down aging process in renal cell culture

Aging renal cell culture experiments with peptide treatment and DNA interaction modeling · Young and aged renal cell cultures

Cartalax and Ovagen increased proliferation, lowered p16, p21 and p53, and raised SIRT-6; modeling placed both peptides in the DNA minor groove at a repeating AT sequence.

Evidence scope: Abstract reviewed; full text not read. Cell culture only, with no animal or human tissue, and the DNA interaction is a computational model.

Main mechanisms of rhabdomyolysis-caused kidney injury and their correction by organospecific peptides

Experimental rhabdomyolysis model of acute kidney injury · Animals with experimental rhabdomyolysis (species not stated in the abstract)

Kidney tripeptides T-31 and T-35, with epitalon, limited tubular cell injury, oxidative stress and energy imbalance, and the authors reported correlations among these mechanisms.

Evidence scope: Abstract reviewed; full text not read. The abstract does not state the species, separate the effect of each peptide, give doses or report group sizes.

Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure

Rat model of cisplatin-induced acute renal failure with peptide treatment · Rats with cisplatin-induced acute renal failure

Ovagen normalized diuresis, urine creatinine concentration and excretion, glomerular filtration rate and absolute sodium reabsorption, and reduced urine protein; the authors called it a potent nephroprotective effect.

Evidence scope: Abstract reviewed; full text not read. Single model, no dose or group size in the abstract, and no long-term follow-up.

Short Peptides Regulate Gene Expression

Computational docking of 19 short peptides to DNA · Spatial models of peptide-DNA complexes, with no cells or animals

Ovagen and Bronchogen docked to ctcc DNA sites; the paper proposes direct DNA binding as a route to gene regulation.

Evidence scope: Abstract reviewed; full text not read. Docking only, with no experimental binding measurement, and the preferred site differs from the repeating AT site reported in the 2014 renal culture paper.

Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis

Rat models of gentamicin-induced nephropathy and ischemia-reperfusion kidney injury · Rats with acute kidney injury from gentamicin or ischemia-reperfusion

Ovagen prevented oliguria and retention azotemia, lowered proteinuria and sodium excretion, prevented the fall in antioxidant enzyme activity, suppressed lipid peroxidation and normalized energy supply.

Evidence scope: Abstract reviewed; full text not read. Two acute models, no dose or group size in the abstract, and no chronic or human data.

The Influence of Peptides on the Morphofunctional State of Kidneys in Old Rats

Study of old rats given a kidney polypeptide complex or the peptides Cartalax, Ovagen or epitalon · Old rats

The kidney polypeptide complex and the tripeptides Cartalax and Ovagen increased diuresis 1.2 to 1.4 times; Ovagen increased sodium excretion 1.6 times; the study reported no morphological or antioxidant evidence of nephrotoxicity.

Evidence scope: Abstract reviewed; full text not read. Group sizes and doses are not in the abstract.

Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters

Molecular docking of 26 ultrashort peptides against LAT1, LAT2, PEPT1 and PEPT2, with 8,400 di- and tripeptides as comparators · Computational models, with no cells or animals

Ovagen ranked fourth of 26 at LAT1 and tenth at PEPT1; it ranked 24th at LAT2 and 25th at PEPT2, so the strongest predicted routes were LAT1 and PEPT1.

Evidence scope: Full text reviewed. Docking only; binding scores do not measure transport, and the authors did not test Ovagen uptake in cells.

History and where it stands today

Ovagen has been studied in kidney cell cultures and in rat models of acute kidney injury, and it has not entered human testing.

  1. 2014Two 2014 papers are central to this kidney literature: one describes Ovagen, also called T-35, in aging kidney cell cultures, and the other tests T-31 and T-35 with epitalon in experimental rhabdomyolysis [1][3].
  2. 2015Ovagen normalizes diuresis, creatinine excretion, glomerular filtration and sodium reabsorption in rats with cisplatin-induced acute renal failure [4].
  3. 2016Docking models place Ovagen at ctcc DNA sites, in a comparison of 19 short peptides [5].
  4. 2017Ovagen prevents oliguria, azotemia and proteinuria and preserves antioxidant enzymes in gentamicin and ischemia-reperfusion nephropathy [6].
  5. 2019In old rats, the kidney polypeptide complex and the tripeptides Cartalax and Ovagen raise diuresis 1.2 to 1.4 times, and Ovagen raises sodium excretion 1.6 times, with no morphological or antioxidant evidence of nephrotoxicity [7].
  6. 2021A systematic review lists it as Ovagen among short peptides and attributes renal regulation, hepatoprotection and DNA binding to it [8].
  7. 2023Docking of 26 ultrashort peptides ranks Ovagen fourth at LAT1 and tenth at PEPT1, with weaker scores at LAT2 and PEPT2 [10].
  8. October 2026As of October 2026, Ovagen has no approved human drug product and no registered clinical trial. WADA's 2026 list does not name it, and S0 covers substances without government approval for human use that no later section addresses [11]; the NCAA 2026-27 list does not name it either, and its peptide-hormone class carries a catch-all [12].

Side effects and safety signals

The safety record for Ovagen comes entirely from cell and animal work, and the human record is empty.

  • In old rats, Ovagen increased sodium excretion, with no morphological or antioxidant evidence of nephrotoxicity [7].
  • In gentamicin and ischemia-reperfusion injury, Ovagen preserved antioxidant enzyme activity and suppressed lipid peroxidation, which suggests it limited oxidative stress in kidney tissue [6].
  • In cisplatin nephropathy, Ovagen improved creatinine excretion and glomerular filtration; the paper reports kidney function and does not list adverse events [4].
  • The animal studies measured kidney function and oxidative stress rather than clinical adverse events, and no human adverse-event or pharmacokinetic data appear in the sources reviewed [4][6].
  • Long-term risk is unmeasured: none of the studies reports chronic toxicology, genotoxicity, reproductive or carcinogenicity testing [4][6][7].
  • The 2021 and 2022 reviews list hepatoprotection, but none of the primary papers reviewed tested liver injury, so liver safety is not characterized [8][9].

The future: what's next for Ovagen

No trial is registered for Ovagen. A ClinicalTrials.gov search for Ovagen on October 23, 2026 returned no study, and the sources reviewed contain no human pharmacokinetic or safety data. A first-in-human study would need a characterized drug substance, an exposure assay and a toxicology package; the sources reviewed contain none of these.

The acute kidney injury models point to the clearest near-term experiments. The 2015 and 2017 papers report benefit across several kidney pathologies, and the 2019 paper proposes Ovagen as a nephroprotective agent in kidney aging [4][6][7]. A repeat-dose study in an aged animal model with measured kidney exposure would test whether the effect persists.

The mechanism needs experimental work. The DNA site differs between the 2014 and 2016 models [2][5], and the 2023 transport scores are docking predictions, not uptake measurements [10].

As of October 2026, Ovagen has no approved human drug product and no registered clinical trial; WADA's S0 class covers unapproved substances and the NCAA peptide-hormone class covers related substances [11][12].

  • Which DNA sequence Ovagen binds in living kidney cells, given that two modeling papers assign different preferred sites [2][5].
  • Whether the kidney protection seen in acute rat injury translates to humans [4][6].
  • How much intact tripeptide reaches kidney tissue after administration, since transport is modeled rather than measured [10].
  • Whether the hepatoprotection listed in the 2021 review is a real, reproducible effect [8].
  • Whether repeated exposure raises immunogenicity or organ toxicity, a question the cited studies do not test [4][6].

Price, research & COA

Quick answers about Ovagen

Price answers use the live price, vendor, and certificate data on this page. Research answers cite the numbered sources below.

What is the cheapest Ovagen listing?

BioLongevity Labs has the lowest 20mg listing at $39.57, checked November 21, 2026.

20mg is the only strength currently listed, shown in the table directly below.

Cheapest in-stock listing by strength
StrengthVendorPriceChecked
20mgBioLongevity Labs$39.57November 21, 2026

Prices apply known public coupon codes; shipping and tax are not included.

Compare current listings →

How much does Ovagen cost?

PeptidePrices currently compares 9 tracked vendors for Ovagen. The median 20mg price is $55.25, checked on November 21, 2026, from a sample of 9 vendors.

20mg is the only strength currently listed.

Median in-stock price by strength
StrengthMedianVendorsPrice range
20mg$55.259$39.57 to $79.99

Prices apply known public coupon codes; shipping and tax are not included.

Compare current listings →

Which Ovagen vendor is best?

No single vendor is best for every researcher. Compare Ovagen vendors on total cost, PeptidePrices quality rating, attached COA evidence, payment options, shipping, and how recently the listing was checked. We encourage researchers to read through our vendor reviews and inspect the attached COAs before making a decision. You can review our methodology here.

Should I pick an Ovagen vendor with a COA?

Yes. The PeptidePrices editorial team generally recommends that researchers only purchase from vendors with COAs attached to their Ovagen listing. If a vendor with a COA doesn't meet all of your buying needs, that's all right: Ovagen currently has 1 vendor with an in-stock listing that carries a matched COA. Without leaving this page, you can open each matched certificate PDF in the on-page viewer and see the issuing laboratory, report date and test panel. You can also read our independent analysis of purity, content, identity, endotoxin and the other panels, then follow the link to verify the certificate on the lab's own record.

Compare listings and their COAs →

How do I find the cheapest Ovagen for the size I want?

The comparison table lists all 9 tracked vendors for Ovagen, sorted by price. Use Size to compare one or more vial strengths, Ships to for the US, Canada, the UK, Australia, the EU or international destinations, and Payment method for credit or debit card, ACH or bank transfer, Zelle, Cash App, Venmo, PayPal, Apple Pay, cryptocurrency or Interac e-Transfer.

Open the comparison →

How can I check the COA on a Ovagen listing?

A vendor's certificate of analysis is attached to its listing when it matches the exact compound, strength and unit. 1 of the 9 vendors currently have an issuer-verified certificate attached. Open it to read the full certificate in an on-page viewer you can zoom, with our summary of the reported results beside it: purity, content and identity, plus endotoxin, sterility, heavy metals and fentanyl screens when the vendor had them tested. To check it yourself, follow the link to the laboratory's own verification record, where the laboratory publishes one, and to the original certificate on the vendor's site.

Open a listing's COA →

Has Ovagen been tested in humans?

No. The sources reviewed contain no human study, and a ClinicalTrials.gov search on October 23, 2026 returned no registered trial. The evidence comes from primary kidney cell cultures and rat models of kidney injury [1][6].

What is Ovagen?

Ovagen is a tripeptide, also called T-35, studied as a tissue-specific bioregulator for the kidney [8][1]. The 2021 systematic review uses the name Ovagen and attributes renal regulation, hepatoprotection and DNA binding to it [8]. The sources do not name a parent protein; the closest natural material is a polypeptide complex from calf kidney [1].

Is Ovagen banned in sport?

WADA's 2026 Prohibited List does not name Ovagen, but S0 prohibits any pharmacological substance with no current government approval for human therapeutic use that no later section addresses [11]. The NCAA 2026-27 list does not name it either; its peptide-hormone class bans substances chemically or pharmacologically related to the class [12].

Sources

  1. Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro agingBulletin of Experimental Biology and Medicine, 2014
  2. Tripeptides slow down aging process in renal cell cultureAdvances in Gerontology, 2014
  3. Main mechanisms of rhabdomyolysis-caused kidney injury and their correction by organospecific peptidesBiofizika, 2014
  4. Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal FailureBulletin of Experimental Biology and Medicine, 2015
  5. Short Peptides Regulate Gene ExpressionBulletin of Experimental Biology and Medicine, 2016
  6. Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different GenesisBulletin of Experimental Biology and Medicine, 2017
  7. The Influence of Peptides on the Morphofunctional State of Kidneys in Old RatsAdvances in Gerontology, 2019
  8. Peptide Regulation of Gene Expression: A Systematic ReviewMolecules, 2021
  9. Transport of Biologically Active Ultrashort Peptides Using POT and LAT CarriersInternational Journal of Molecular Sciences, 2022
  10. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family TransportersBiomolecules, 2023
  11. The 2026 Prohibited ListWorld Anti-Doping Agency, 2026
  12. 2026-27 NCAA Banned SubstancesNational Collegiate Athletic Association, 2026

Related pages

More on Ovagen